Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06952803 · ClinicalTrials.gov registry record · Phase 3

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation

A Phase 3 study of Prostate Cancer, sponsored by AstraZeneca.

Recruiting
Registry status
Phase 3
Development phase
700
Enrollment target
20
Study locations

NCT06952803 is a Phase 3 study of Prostate Cancer that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 700 participants, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (15% higher). The trial reports 20 study locations across 9 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06952803, a Phase 3 study of Prostate Cancer, is actively recruiting participants, sponsored by AstraZeneca.

RECRUITING
Registry status
Phase 3
Development phase
700 participants
Enrollment target
20
Study locations

Study Summary

The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm).

Conditions Studied

Prostate Cancer

Interventions

  • DRUG Placebo
  • DRUG Androgen Deprivation Therapy (ADT)
  • DRUG Saruparib
  • DRUG Abiraterone + Prednisolone/Prednisone

Study Locations (20)

California

  • Research Site - La Jolla
  • Research Site - La Jolla
  • Research Site - Los Angeles
  • Research Site - San Diego
  • Research Site - San Diego
  • Research Site - San Luis Obispo

Florida

  • Research Site - Hialeah
  • Research Site - Jacksonville
  • Research Site - Tampa

Arizona

  • Research Site - Phoenix
  • Research Site - Tucson

Illinois

  • Research Site - Chicago
  • Research Site - Chicago Ridge

Indiana

  • Research Site - Greenwood
  • Research Site - Jeffersonville

Maryland

  • Research Site - Bethesda
  • Research Site - Towson

Colorado

  • Research Site - Lakewood

Georgia

  • Research Site - Newnan

Trial Details

FieldValue
Enrollment Target 700 participants
Start Date 2025-08-06
Est. Completion 2036-04-30
Phase Phase 3

Sponsor

AstraZeneca

1,285 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06952803

The ClinicalTrials.gov registry entry for NCT06952803 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 607-participant average among 735 other Prostate Cancer trials with a reported enrollment target (15% higher). The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Prostate Cancer appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT06952803 reports 20 study locations spanning 9 distinct geographic areas - top geographies include California, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT06952803 about?

NCT06952803 is a clinical study titled "A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation". The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally adva...

What is the current status of trial NCT06952803?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2025-08-06. Estimated completion is 2036-04-30.

What conditions does trial NCT06952803 study?

This clinical trial studies the following conditions: Prostate Cancer.

What interventions are being tested in trial NCT06952803?

The interventions under investigation include: Placebo (DRUG), Androgen Deprivation Therapy (ADT) (DRUG), Saruparib (DRUG), Abiraterone + Prednisolone/Prednisone (DRUG).

Who is sponsoring clinical trial NCT06952803?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06952803 being conducted?

This trial has 20 study locations across Arizona, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Prostate Cancer

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.